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Abstract 
Intraplaque hemorrhage (IPH) is an important progression event in advanced atherosclerosis,
in large part due to the delivery of pro-oxidant hemoglobin in erythrocytes.We have 
previously defined a novel macrophage phenotype (HA-mac) in human advanced plaques 
with IPH. These may be atheroprotective in view of raised heme oxygenase 1 (HO-1), CD163 
and interleukin 10 (IL-10) expression and suppressed oxidative stress. We have used a
combination of siRNA and pharmacological reagents, protein analysis and oxidative stress 
measurements to dissect the pathway leading to the development of this phenotype. We found 
that erythrocytes, Hb, or purified heme similarly induced CD163, and suppressed HLA-DR 
and reactive oxygen species. HO-1 was required for the development of each of these 
features. Challenge of macrophages with purified heme provoked nuclear translocation of 
Nrf2, and Nrf2 siRNA resulted in significant inhibition of the ability of heme to induce HO-1
protein. Furthermore, tert-butyl-hydroquinone, which activates Nrf2, upregulated CD163, 
suppressed HLA-DR and induced IL-10, further supporting a role for Nrf2-mediated 
signalling. However, an inducible protein transactivator is also probably necessary, as heme-
induced HO-1 mRNA expression was fully inhibited by the protein synthesis inhibitor 
cycloheximide. In conclusion, our experiments define an Nrf2-mediated pathway by which 
heme induces a homeostatic macrophage response following IPH. (200) 
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Introduction
Intraplaque hemorrhage (IPH) is a key determinant of atherosclerosis progression and plaque 
destabilisation 1. IPH results in the delivery of both cholesterol-enriched membrane lipids and 
hemoglobin (Hb) to the plaque interior 1-3, an environment already challenged by 
accumulated cholesterol and oxysterols 1, 4. As the iron in heme is an effective peroxidant 
catalyst via H2O2 coordination and Fenton chemistry 5, Hb deposition enhances the  lipid 
peroxidation of cholesterol  2. This in turn can activate macrophage release of H2O2 and free 
radicals 6. Since IPH induces monocyte recruitment 1, how monocytes respond to Hb is 
critical in determining the outcome of hemorrhage.
Heme is catabolized by cytoprotective heme oxygenases into free ferric ions, biliverdin and 
carbon monoxide (CO) 7. Low levels of CO, like nitric oxide, engage protective cell 
signalling pathways such as soluble guanylate cyclase 7. Free ferric ions are normally quickly 
chelated by co-induced ferritin, where they are safely locked out of Fenton activity 7.
Biliverdin is further converted by biliverdin reductase to bilirubin, an endogenous antioxidant
7. HO has two isoforms, with HO-1 being inducible by heme and many other agonists, and 
HO-2 being constitutively expressed 7. The inducibility of HO-1 by heme provides a key 
negative feedback loop, protecting phagocytes from oxidative stress associated with free iron
5. Surprisingly, there is relatively little published information on how heme induces HO-1, 
when compared with the large investment of effort in inflammatory or pharmacological 
stimuli 7.
We have recently identified a discrete phenotype of macrophages, designated HA-mac, that
are localized around hematoma in human plaques with fatal coronary thrombosis 6. When 
compared to more typical macrophage foam cells within the same plaque, these are
characterized by suppressed oxidative stress, myeloperoxidase and activation marker HLA-
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DR, and increased HO-1 expression and interleukin-10 6. Culturing human blood-derived 
monocytes with hemoglobin-haptoglobin complexes (Hb:Hp) over 4-8 days reproduced these
phenotypic features, which were prevented by inhibiting the anti-inflammatory cytokine IL-
10, or by inhibiting CD163 dependent endocytosis with cytochalasin-D or with CD163-
siRNA 6.
The basic biochemistry of the transcription factor Nrf2 has been extensively reviewed 8. Nrf2 
is activated by oxidative stress and electrophiles, due to conversion of cystine residues to 
cysteine (ie disulphide crosslinking) in an inhibitory partner Keap-1 8. Activated Nrf2 
translocates to the nucleus and binds to antioxidant response elements 8. The electrophile tert-
butyl hydroquinone (t-BHQ) is extensively used as a selective Nrf2 activator 8.  
CD163 is a macrophage scavenger receptor for Hb:Hp complexes, and functions primarily as 
a means for their internalisation 9. However, CD163 may also have signalling functions, as 
suggested by the effects of ligation by antibodies 10. If macrophage CD163 functions
primarily as an endocytic rather than a signalling receptor, then other modes of entry of 
erythrocyte degradation products should induce HA-mac features. In this paper we
demonstrate that this indeed occurs following exposure of monocytes to oxidized red blood 
cells (OxRBC) or free heme, and that this involves a final common pathway mediated by
activation of Nrf2.
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Methods 
A full description of the Methods is found Online. These are previously described, with 
modification where indicated 6.  Blood was collected from normal volunteers, and monocytes 
were aseptically purified and cultured as previously described. RNA was spin-column-
purified and analysed by RT-qPCR using standard molecular biology methods. Western 
blotting was by standard methods using a precast gel system (Novex, Invitrogen), commercial 
antibodies and chemiluminescence (ECL Plus, GE Healthcare). Confocal microscopy was 
with a Zeiss LSM-510Meta using standard settings. RNAi of human monocytes was by using 
a modification of our previously described methods. Flow cytometry was by modification of 
previously described methods, using standard live cell immunofluorescence staining and a 
Dako CyAN cytometer. 
Results 
We tested whether CD163-independent entry of Hb would drive undifferentiated monocytes 
to the HA-mac phenotype. Oxidatively damaged erythrocytes (OxRBCs) contain Hb, are 
pathophysiologically relevant and are known to be phagocytosed via macrophage scavenger 
receptor A (MSR1, MSRA, CD204) rather than by CD163 11, 12. On the other hand, heme 
does not require a receptor to enter cells, as it is lipid soluble and freely membrane permeant.
As shown in Figure 1, culturing monocytes for 6 days with oxidatively damaged erythrocytes 
(OxRBCs), or with purified heme, increased surface CD163 and decreased surface HLA-DR
in the same manner as Hb:Hp complexes. This result is therefore consistent with a common 
mechanism of monocyte response to Hb that is not dependent on CD163.
Since macrophage oxidants play an important role in driving atherosclerosis, we developed 
an assay using aminophenyl fluorescein (APF), which has been previously validated to detect
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hypochlorite, hydroxyl free radical and peroxynitrite (collectively termed highly reactive 
oxygen species, hROS) 13. As part of basic assay characterisation, we found that OxLDL 
evoked macrophage hROS (Supplemental Figure I) but other agonists (TNF, LPS, POVPC, 
IFN) had minimal effect under the assay conditions used (not shown). OxLDL-evoked 
hROS were at least partly dependent on myeloperoxidase, evidenced by suppression by the 
selective MPO inhibitor 4-amino-benzoic acid hydrazide (4-ABH) (Supplemental Figure IA)
and were maximal with 30g.mL-1 OxLDL after 2 days culture (Supplemental Figure IB,C). 
OxLDL had no effect on APF in the absence of macrophages (not shown). OxLDL was 
particulate with a fraction of the total in the 1-10m range (Supplemental Figure ID,E), and 
OxLDL-evoked hROS were suppressed by cytochalasin-D, indicating that phagocytosis was 
required (Supplemental Figure IF). Adding 10m polystyrene microbeads, which are 
phagocytosable but otherwise inert, to these cultures at a ratio of 1 bead/cell also evoked 
hROS (Supplemental Figure IG), indicating that phagocytosis itself may lead to hROS 
generation. Together, this set of experiments validated OxLDL as a plaque-relevant 
phagocytic stimulus for a macrophage oxidative burst and generation of pathogenic reactive 
species (hROS). This was then used as a standard assay for macrophage oxidative stress.
When human monocyte-derived macrophages were incubated with OxRBCs, heme or Hb:Hp 
for 2 days and then challenged with OxLDL, OxRBCs and heme suppressed hROS to an even
greater extent than Hb:Hp complexes (ANOVA, p<0.05, Figure 1D). Importantly, this effect 
required macrophages, since heme and hydrogen peroxide were strongly synergistic for APF-
fluorescence in a cell free system (Figure 1E). This is consistent with the known Fenton-
chemistry of heme in the presence of hydrogen peroxide and provides a positive control for 
the assay.
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Since the effect of Hb:Hp, OxRBCs and heme appeared similar, we next asked whether 
erythrocytes and Hb:Hp complexes liberated heme once within the macrophages. As
porphyrins have characteristic visible-light absorption profiles, we first used visible 
spectrophotometry (Supplemental Figure II). Reference spectra for Hb and heme from 400nm 
to 800 nm were consistent with those previously published 14. Hb had characteristic Soret 
peaks while heme had a broader absorption profile, with a shoulder from 400-450nm
(Supplemental Figure IIA,B). We found that the absorption profile of Hb:Hp complexes 
became like that of heme after co-incubation with macrophages (Supplemental Figure IIC).
We then carried out the same procedure for OxRBCs and again found a change in the overall 
spectrum following incubation with macrophages, in a pattern consistent with release of 
heme (Supplemental Figure IID). Measurement of free heme using a commercially available 
chemical assay broadly corroborated the spectroscopy data, with a maximum heme release 
from Hb:Hp complexes at 3 days, and generation of relatively large concentrations of 
intracellular heme in response to OxRBC treatment (Supplemental Figure IIE,F).
As heme is potentially pro-oxidant, we questioned whether there the heme-induced anti-
oxidant state is preceded by oxidative stress (Supplemental Figure III). Indeed, treatment with 
purified heme (10M) increased generation of hROS at 1h, and this returned to baseline at 4h 
and reversed to an anti-oxidant effect by 48h. However oxidative stress alone is unlikely to 
explain the development of the HA-mac phenotype as two other oxidative stress stimulants,  
H2O2 (100nM-10M) and the purified synthetic oxylipid palmitoyl-oxo-valeryl-
phosphatidylcholine (POVPC) 15, failed to lead to late suppression of hROS generation or 
HLA-DR expression or to an increase in CD163 (Supplemental Figure IV).
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We next tested whether phagocytosed Hb:Hp complexes or erythrocytes traffic into 
lysosomes. Using live-cell confocal microscopy, Alexa488-labelled Hb:Hp complexes were 
seen to internalise and traffic to lysosomes, as indicated by colocalisation with the lysosomal 
marker LysoTracker Red. Thus, Figure 2A shows green-labelled Hb and red labelled 
lysosomes superimposed as yellow, indicating that Hb colocalises with lysosomes as far as 
can be determined by optical microscopy. We then extended this analysis to calcein-labelled 
OxRBCs. A low magnification image taken seconds after addition showed labelled 
erythrocytes surrounding the macrophages (Figure 2B). In contrast, images taken after 20
mins showed OxRBCs (green-labelled) in lysosomes (red-labelled), with yellow coloured 
areas in the overlay indicating colocalization (Figure 2C). In contrast, non-internalised 
erythrocytes were entirely green at this point, indicating they were devoid of lysosomal 
coating (Figure 2D). 
To ask whether generation of HA-mac features requires lysosomal function, we tested the 
effect of chloroquine16. In unstimulated macrophages, chloroquine suppressed HLA-DR with 
minimal effect on surface CD163 in a concentration-dependent manner from 100nM– 10M
(Figure 3A). The lowest effective concentration was chosen for subsequent experiments 
(1M). In contrast, chloroquine (1M) instead increased HLA-DR in macrophages cultured 
in the presence of OxRBCs (Figure 3B), or with Hb:Hp (Figure 3C). In parallel, chloroquine 
(1M) inhibited the induction of surface CD163 with OxRBCs or Hb:Hp complexes (Figure 
3B,C). As a control, chloroquine (1M) had minimal effect on either CD163 or on HLA-DR
in heme-treated macrophages (Figure 3D). With the specificity provisos of a pharmacological 
inhibitor, this therefore suggests that inhibiting lysosomes prevents the CD163hi HLA-DRlo
phenotype upon challenge with complex hemorrhage-products that are a source of heme, but 
does not suppress equivalent responses to heme itself.
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An important anti-inflammatory and anti-oxidant gene induced by heme is HO-1 7. As shown 
in Supplemental Figure V, macrophages differentiated with Hb:Hp complexes had increased 
HO-1 as assessed by fluorescence image analysis (Supplemental Figure V). This increased 
HO-1 was in part colocalized with CD68 (macrosialin), a specific marker of macrophage 
lysosomes (Supplemental Figure V). HO-1 was not identified in unstimulated cells.
We then determined the contribution of HO-1 to the anti-oxidant profile of heme-stimulated 
cells, using OxLDL or serum deprivation (serum-free medium, SFM 17, 18) as stimuli for 
oxidative stress. Heme suppressed macrophage hROS (Figure 4A), and this protection was 
strongly reversed in the presence of the specific HO-1 inhibitor 10M zinc protoporphyrin 
(ZnPP)19, 20 (Figure 4B). ZnPP also reduced macrophage survival in culture over 6 days, 
whereas both heme and the specific HO-1 activator cobalt protoporphyrin (CoPP)19, 20 had the 
opposite effect, each in a concentration-dependent manner over 100nM-10M (Figure 4C). 
Furthermore, both the increase in CD163 and suppression of HLA-DR induced by heme were 
antagonized by ZnPP (300nM-3M) (Figure 4D). Conversely, surface levels of CD163 were 
increased and HLA-DR decreased by 3M CoPP (Figure 4E). Of note, 10M CoPP induced 
macrophage IL-10 after 48 hours culture, consistent with our previous finding that HA-mac 
are mediated by autocrine IL-10 6 (Figure 4F).
Aware of the caveats of pharmacological reagents, we next used siRNA to further test the
contribution of HO-1 to the development of HA-mac features (Figure 5). We found that 
freshly isolated monocytes took up labelled siRNA avidly (Figure 5A). Using the same 
protocol with unlabelled HO-1-specific or scrambled siRNA, we determined HO-1
expression by western blotting (Figure 5B). This confirmed that heme strongly induces HO-1,
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and showed that this was specifically ablated by HO-1-siRNA (Figure 5B). Relative to 
control transfection, HO-1 siRNA reversed the anti-oxidant effect of Hb:Hp complexes on 
macrophage hROS triggered by OxLDL (Figure 5C). Similarly, heme-induced suppression of 
hROS was also reversed to a strongly pro-oxidant effect with HO-1 siRNA (Figure 5D).  
Furthermore, HO-1 siRNA reversed the suppression of HLA-DR and inhibited the induction 
of CD163 on day 6 macrophages by heme (Figure 5E, F).  Finally, HO-1 siRNA inhibited 
heme-induced IL-10 secretion (Figure 5G). Thus, HO-1 induction is necessary for CD163 
induction, HLA-DR suppression and suppression of hROS induced by erythrocytes, Hb and 
free heme.  
We next assessed changes in levels of HO-1 mRNA in response to heme, and found that 
these were near maximally elevated by 10M heme (Supplemental Figure VI). In a time-
course analysis, we found that there was minimal induction at 1 hour but near-maximal 
expression by 4 hours (Supplemental Figure VI). We therefore chose 10M and 4h as 
standard conditions to test the role of Nrf2 in induction of HO-1. Purified heme (Figure 6A) 
or Hb:Hp (not shown) evoked clear-cut nuclear translocation of Nrf2 to the nucleus when 
added to monocytes. Moreover, Nrf2-siRNA, which suppressed Nrf2 protein by over 89%, 
decreased the ability of heme to induce HO-1 protein by approximately 50% (Figure 6B). 
Further support for a role for Nrf2 signalling came from the use of the known Nrf2 activator 
tert-butyl-hydroquinone (t-BHQ)21, which suppressed heme-induced hROS in a concentration 
dependent manner, maximal by 10M (Figure 6C). Similarly, 50M t-BHQ evoked IL-10 
secretion (control 71.8 ± 21.8; t-BHQ 477±40 pg.mL-1) and induced a subpopulation with 
upregulated CD163 and reciprocally suppressed HLA-DR (Figure 6 D).  
As established above, oxidant stress alone does not induce the HA-mac phenotype, 
suggesting that Nrf2 activation is not sufficient. Consistent with this, we found that heme-
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induction of HO-1 mRNA was completely suppressed in monocytes from 12 separate donors 
by the protein synthesis inhibitor cycloheximide (100M), without loss of cell viability 
(Supplemental Figure VI). As Nrf2-mediated transcriptional activation does not require de 
novo protein synthesis, these observations therefore indicate that the induction of HO-1
mRNA in monocytes by heme also requires synthesis of an induced intermediary protein 
transactivator.
Discussion 
The data presented in this paper provide fresh insights into the origins of the HA-mac
phenotype in haemorrhaged plaques6 by showing that the phenotype is driven by 
internalisation of Hb:Hp or erythrocytes complexes followed by the release of heme. We
have established for the first time that heme induces HO-1 expression, in part via Nrf2. HO-1
is then required for the increase in CD163, suppression of HLA-DR and suppression of
oxidative stress. We therefore propose that a heme  Nrf2  HO-1 pathway is part of a
‘final common pathway’ for HA-mac differentiation.
We have demonstrated that Hb:Hp complexes and oxidized erythrocytes are internalized by 
macrophages, sent to lysosomes and then liberate heme. This induces HO-1, which is itself 
trafficked to lysosomes. Using HO-1 inhibitors and inducers, we have found that the induced 
HO-1 is necessary for hemorrhage products to evoke the features of HA-mac. Taking these 
data together, we suggest a unifying schema whereby hemorrhage-related degradation 
products enter macrophages (Supplemental Figure VII). Heme is lipophilic and freely passes 
cell membranes. On the other hand Hb:Hp complexes undergo receptor-mediated endocytosis 
via CD163, and OxRBCs are internalized via CD204 / MSRA11, 12. As far as can be 
determined with state-of-the-art reagents and microscopy, internalised products are passed to 
lysosomes, where the globin scaffold is proteolysed, liberating heme. This framework goes 
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against the concept that CD163 ligation by Hb:Hp complexes initiates a classical protein 
phosphorylation signalling cascade that directly causes the HA-mac transcriptional response.
Nrf2 is a cap’n’collar transcription factor activated by oxidation of cysteines on its inhibitory
partner, Keap 22. Thus, Nrf2 is activated by cellular oxidative stress or electrophiles and its 
target genes include many that decrease oxidative stress (e.g. superoxide dismutase, HO-1) or 
induce Phase-II metabolism (which catabolises exogenous electrophiles, e.g. xenobiotics) 22.
Given this background, Nrf2 was a priori a strong candidate to mediate adaptive macrophage 
responses to heme 23, and this was supported both by experimental activation with t-BHQ and 
by gene silencing with siRNA.  We cannot find a previous mechanistic dissection of the role 
of Nrf2 in HO-1 induction by heme, the physiological substrate for this enzyme.  
Interestingly, Kadl et.al. have recently published a landmark paper on Nrf2 and HO-1in
mouse macrophages, 24. They stimulated mouse macrophages with the synthetic lipid PAPC,
which they had purchased and oxidised in-house (to presumed OxPAPC) by passive exposure 
to atmospheric oxygen. OxPAPC and POVPC are defined oxylipids related to phosphatidyl-
choline, found in minimally modified LDL and which have been extensively characterised as 
being bioactive 15. OxPAPC evoked a macrophage transcriptome pattern, designated by the 
authors as Mox, that included induction of HO-1, along with sulfiredoxin and thioredoxin
genes. This did not occur in Nrf2-null mice, indicating that Nrf2 was required for HO-1
induction in this model24. Nrf2-mediated induction of HO-1 via the antioxidant response 
element (ARE) has been previously described in response to a wide variety of stimuli, 
including toxic electrophiles, dietary (vegetable) indirect antioxidants and cigarette smoke 23,
25-32. While the Mox transcriptome analysis sets the OxPAPC-responding geneset apart from 
M1 and M2 subsets in the mouse, it remains to be seen whether this represents a genuinely 
committed stable lineage or a plastic state. Notwithstanding, our own treanscriptome analysis 
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of HA-Mac clearly distinguishes this putative atheroprotective phenotype from Mox as well 
as M1 and M2 cells (Boyle et al, submitted for publication).
A strength of our study has been the use of freshly isolated cells. Transcriptome analyses of 
plaque macrophages and pooled cell line microarray data indicate that gene expression in 
freshly isolated blood-derived monocytes is relevant to plaques 33. Moreover, a meta-analysis 
of microarray data giving a global map of human gene expression has revealed enormous 
differences between transformed cell-lines and primary tissues34. Thus although human 
blood-derived monocytes are difficult to transfect, they are likely to be to be far more 
informative about human pathophysiology. However, the use of fresh human cells has 
limitations, not least the difficulty of obtaining a complete knock-down using siRNA. We 
corroborated data with siRNA and extensively characterised pharmacological inhibitors,
establishing concentration-dependent action with effects at appropriate concentrations16, 19-21.
We cannot be sure to what degree the relatively modest reduction in HO-1 seen in cells 
treated with Nrf2 siRNA was due to gene silencing being only partial (89%) or to what 
degree it reflects the status of Nrf2 as just one of the transcription factors necessary for 
eliciting HA-mac features. The latter seems likely, as an experiment with cycloheximide 
showed that induction of HO-1 mRNA requires protein synthesis as an intermediary step. The 
identification of transactivators that operate in this system and which may deviate the stress 
response towards HA-mac rather than Mox phenotype 24 is the subject of a separate 
manuscript (Boyle et al, submitted for publication).
In conclusion, uncommitted monocyte-derived macrophages respond to intraplaque 
hemorrhage by internalising Hb:Hp complexes and/or oxidized red blood cells into 
lysosomes, resulting in the intracellular release of free heme. This in turn induces HO-1, in 
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part via Nrf2, which leads to a phenotype similar that we have previously identified in the
vicinity of haemorrhage in human plaques.
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Figure Legends 
Figure 1: Hb:Hp complexes, heme and oxRBCs all induce a macrophage CD163hi
HLA-DRlo phenotype Flow cytometry for CD163, HLA-DR or isotype control antibody as
indicated, in human monocyte-derived macrophages (Mø) after 6 days culture. Monocytes 
were cultured from the start in the presence of (A) heme (10 M), (B) Hb:Hp (100 nM), or 
(C) OxRBCs (ratios as indicated). Veh = control cells cultured with vehicle. Iso = staining 
with isotype-matched control antibody. Data are representative of five experiments on five 
subjects each; (D) Human monocyte-derived macrophages were cultured for 48 hours, after 
which medium was changed to PBS containing aminophenylfluorescein (APF) and OxLDL
(10 g.mL-1). hROS were measured after a further 18 hours incubation; (E) Cell-free wells 
contained APF in PBS were incubated with purified heme (1 mM) and/or hydrogen peroxide 
(1 mM) and hROS measured after 18 hours incubation. Values are mean + SE, P<0.05 with 
Bonferroni’s correction, ANOVA.
Figure 2: Lysosomal colocalisation of ingested erythrocytes or HbHp complexes (A) Hp
was labelled with Alexa488 (green), conjugated with Hb (1:1 molar ratio) and added to 
macrophages labelled with the lysosomal marker LysoTracker Red. The images were taken 
with a x63 objective after 20 min. (B-D) Autologous erythrocytes were oxidatively damaged 
(1mM H2O2 for 20 mins), labelled with calcein (green) and added to LysoTracker Red 
labelled macrophages. Images were acquired after 1 min (B), 20 min (C) and 22 min (D) with 
a x20 objective (B) or a x63 objective (C,D) respectively. Red = lysosomes of varying sizes, 
some below optical resolution, larger lysosomes are pointed to by arrowheads (Ly); e = some 
of the calcein-labelled erythrocytes; M = macrophage. Scalebars = indicated distance.  
Colocalisation of green and red is indicated by yellow (representative areas, open arrows).
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Figure 3: Lysosomes are required for macrophage response to erythrocytes and Hb:Hp 
complexes Freshly isolated monocytes were cultured with chloroquine (10M), a lysosomal 
inhibitor, either alone (A) or in combination with (B) OxRBCs (10:1 
erythrocytes:macrophages), (C) Hb:Hp complexes (100nM) or (D) purified heme (10M) for 
6 days. Expression of CD163 and HLA-DR was then assessed by flow cytometry. Data are 
representative of four donors. Iso = staining with isotype-matched control antibody 
Figure 4: HO-1 is required for the macrophage response to heme (A) Monocytes were 
cultured in medium alone (open-bars) or in the presence of heme (10M) for 2 days. Then 
1M APF was added with OxLDL (30 g.mL-1) or medium was removed, cells were washed 
twice in serum free medium (SFM) and then incubated in SFM with 1M APF; (B)
Monocytes were cultured and challenged as in (A), but in the presence or absence of ZnPP
(10M); (C) shows the normalised cell number of monocytes cultured over six days in the 
presence of heme, ZnPP, or CoPP (each over a concentration-effect curve 100 nM-100 M);
(D, E) shows HLA-DR and CD163 expression in cells differentiated over 6 days with (D)
heme (10 M) and varying concentrations of ZnPP or (E) CoPP (10 M); (F) flow cytometry 
histograms for intracellular IL-10 on monocytes incubated with CoPP (10 M) over two 
days. Values are mean ± SE, with five subjects. P<0.05, ANOVA with Bonferroni’s 
correction where appropriate. Iso = staining with isotype-matched control antibody.
Figure 5: HO-1 is required for macrophage response to heme (A) We added transfection 
reagent (PEI) alone or transfection reagent plus FITC-labelled siRNA immediately after 
monocyte purification, and uptake assessed after 24h culture. The x-axis shows uptake of 
FITC-labelled siRNA oligonucleotides into human monocytes at the start of culture and the 
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y-axis shows the cell number. Data are representative of three experiments; (B) Western 
blotting for HO-1 27 kDa protein in extracts of monocytes cultured for 4 hours in the 
presence or absence of heme and siRNA; after 24h of siRNA added from the start of culture.
Scr = scrambled control; (C, D) show reversal by HO-1 siRNA of effects of HbHp (C) and 
heme (D) on hROS release by monocytes cultured for 2 days. Data are mean ± SE, n=5 
subjects; (E-G) show reversal by HO-1 siRNA of effects of heme on (E) HLA-DR 
expression, (F) CD163 expression and (G) IL-10 release by monocytes cultured for 2 days. 
Data in histograms are mean ± SE, with five donors.* p<0.05, Student’s t-test. Iso = staining 
with isotype-matched control antibody.
Figure 6: Heme induces HO-1 via Nrf2. Human monocytes were rested overnight before 
challenging with heme. (A) Confocal immunofluorescence staining of Nrf2 localisation at 4 
hours, with Nrf2 in green and nuclear dye (TOPRO) in red. Yellow staining implies nuclear 
colocalisation of Nrf2. Inset = low magnification (vehicle) or staining control (heme-treated). 
Representative of n=3 experiments; (B) Western blots of Nrf2, HO-1 and -actin (loading 
control) in lysates of cells treated with siRNA for Nrf2 or control siRNA as indicated. Lower 
panels show densitometry quantification of Nrf2 or HO-1 (mean ± SE, n=3); (C, D)
Monocytes were cultured with the Nrf2 activator t-BHQ over the concentration effect curve 
1-100M for assayed for (C) hROS at day 2 and (D) expression of HLA-DR and CD163 at 
day 6. *, ANOVA with Bonferroni’s adjustment; maximum effect of t-BHQ is at 10M.
Arrow in D points to a population within the ellipse with increased CD163 and reduced 
HLA-DR. Suppression of hROS by t-BHQ was also seen at culture day 6 (not shown). 
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